Abstract 3300: Aspirin and Medium Intensity Coumadin versus Aspirin Alone in the Prevention of Reocclusion After Successful Thrombolysis for Suspected Acute Myocardial Infarction: 5-Year Follow-Up of the APRICOT-2 Trial

Background: The Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis (APRICOT)-2 trial showed that medium intensity coumadin (INR 2–3) added to aspirin reduces angiographic and clinical reocclusion in the first three months after successful thrombolysis. This analysis assesses whether the observed early clinical benefit is sustained at 5-year follow-up. Methods: In the APRICOT-2 trial 251 patients ( Results: Reocclusion rates (TIMI flow Conclusions: The early clinical benefit from medium intensity coumadin added to aspirin after successful thrombolysis is sustained at five-year follow-up. This benefit is attributed to a reduced risk for reocclusion. These observations support a role for prolonged anticoagulation in this setting.